Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Single-dose RepliVax vaccine to prevent tick-borne encephalitis (TBE)

A single-cycle virus vaccine platform, RepliVax, could help generate vaccines to protect against TBE. The single-cycle virus vaccine (RepliVax-TBE) was constructed using a West Nile virus backbone with deletion of the capsid gene and insertion of TBE virus envelope genes. In outbred mice, intraperitoneal immunization with RepliVax-TBE induced a protective immune response and increased survival against a lethal challenge with a TBE-related virus compared with mock immunization. In nonhuman primates, a single dose of RepliVax-TBE protected from challenge with a TBE-related virus and induced more durable immune responses compared with an inactivated human TBE virus vaccine. Next steps include evaluating the breadth of protection conferred by RepliVax-TBE against circulating wild-type TBE strains representing three major genotypes.

SciBX 6(31); doi:10.1038/scibx.2013.844
Published online Aug. 15, 2013

Patented by Sanofi Pasteur; licensing status undisclosed

Rumyantsev, A.A. et al. Proc. Natl. Acad. Sci. USA; published online July 15, 2013;
doi:10.1073/pnas.1306245110
Contact: Konstantin V. Pugachev, Sanofi Pasteur, Discovery US, Cambridge, Mass.
e-mail:

konstantin.pugachev@sanofipasteur.com